

10/019661

REC'D 23 DEC 1999

WIPO PCT

REGISTRY OF PATENTS
SINGAPORE

This is to certify that the annexed is a true copy of the following Singapore patent application as filed in this Registry.

Sg 00 / 128

Date of Filing : 02 JULY 1999

Application number : 9903146-0

Applicants : INSTITUTE OF MOLECULAR
AGROBIOLOGYTitle of Invention : GLOBAL REGULATORS OF BACTERIAL
PATHOGENIC GENES AS TARGETS FOR
ENGINEERING DISEASE RESISTANCE

I further certify that the annexed documents are not, as yet, open to public inspection.

PRIORITY
DOCUMENTSUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)Liew Woon Yin (Ms)
Registrar of Patents
Singapore

08 December 1999

9903146-0

PATENTS FORM 1

**SINGAPORE
THE PATENTS ACT
(CHAPTER 221)
THE PATENTS RULES**

Rule 19

**The Registrar of Patents
Registry of Patents**

REQUEST FOR THE GRANT OF A PATENT

THE GRANT OF A PATENT IS REQUESTED BY THE UNDERSIGNED ON THE BASIS OF THE PRESENT APPLICATION.

I Title of Invention	GLOBAL REGULATORS OF BACTERIAL PATHOGENIC GENES AS TARGETS FOR ENGINEERING DISEASE RESISTANCE			
II Applicant(s) (See note 2)	(a) Name	Institute of Molecular Agrobiolology		
	Body Description/ Residency	Incorporated under the laws of Singapore		
	Street Name & Number	1 Research Link The National University of Singapore		
	City			
	State	117604		
	Country	Singapore		
	(b) Name			
	Body Description/ Residency			
	Street Name & Number			
	City			
	State			
	Country			
	(c) Name			
	Body Description/ Residency			
	Street Name & Number			
	City			
	State			
	Country			
III Declaration of priority (See note 3)	Country/Country Designated		File No	
	Filing Date			
	Country/Country Designated		File No	
	Filing Date			
	Country/Country Designated		File No	
	Filing Date			

SECOND SCHEDULE - continued

IV Inventors <i>(See note 4)</i> (a) The applicant(s) is/are the sole/joint inventor(s) (b) A statement on Patents Form 8 is/will be furnished	<div style="display: flex; justify-content: space-around;"> <div> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No </div> <div> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No </div> </div>		
V Name of Agent (if any) <i>(See note 5)</i>	Ella Cheong & G Mirandah		
VI Address for Service <i>(See note 6)</i>	Block/Hse No		Level No
	Unit No/PO Box	0931	Postal Code
	Street Name		
	Building Name	Raffles City	
VII Claiming an earlier filing date under section 20(3), 26(6) or 47(4) <i>(See note 7)</i>	Application No		
	Filing Date		
VIII Invention has been displayed at an International Exhibition <i>(See note 8)</i>	<div style="display: flex; justify-content: space-around;"> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No </div>		
IX Section 114 requirements <i>(See note 9)</i>	The invention relates to and/or used a micro-organism deposited for the purposes of disclosure in accordance with section 114 with a depository authority under the Budapest Treaty. <div style="display: flex; justify-content: space-around;"> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No </div>		
X. Check List <i>(To be filled in by applicant or agent)</i>	A. The application contains the following number of sheet(s):-		
	1 Request	3	sheets
	2 Description	31	sheets
	3 Claim(s)	4	sheets
	4 Drawing(s)	8	sheets
	5 Abstract	1	sheets
	B. The application as filed is accompanied by:-		
1 Priority document			
2 Translation of priority document			
3 Statement of Inventorship & right to grant			
4 International Exhibition Certificate			
X. Signature(s) <i>(See note 10)</i>	Applicant (a)		
	Date	2 July 1999	
	Applicant (b)		
	Date		
	Applicant (c)		
	Date		

SECOND SCHEDULE - continued

NOTES:

1. This form when completed, should be brought or sent to the Registry of Patents together with the prescribed fee and 3 copies of the description of the invention, and of any drawings.
2. Enter the name and address of each applicant in the spaces provided at paragraph II. Names of individuals should be indicated in full and the surname or family name should be underlined. The names of all partners in a firm must be given in full. The place of residence of each individual should also be furnished in the space provided. Bodies corporate should be designated by their corporate name and country of incorporation and, where appropriate, the state of incorporation within that country should be entered where provided. Where more than three applicants are to be named, the names and address of the fourth and any further applicants should be given on a separate sheet attached to this Form together with the signature of each of these further applicants.
3. The declaration of priority at paragraph III should state the date of the previous filing, the country in which it was made, and indicate the file number, if available. Where the application relied upon in an International Application or a regional patent application e.g. European patent application, one of the countries designated in that application [being one falling under the Patents (Convention Countries) Order] should be identified and the name of that country should be entered in the space provided.
4. Where the applicant or applicants is/are the sole inventor or the joint inventors, paragraph IV should be completed by marking the "YES" Box in the declaration (a) and the "NO" Box in the alternative statement (b). Where this is not the case, the "NO" Box in declaration (a) should be marked and a statement will be required to be filed on Patents Form 8.
5. If the applicant has appointed an agent to act on his behalf, the agent's name should be indicated in the spaces available at paragraph V.
6. An address for service in Singapore to which all documents may be sent must be stated at paragraph VI. It is recommended that a telephone number be provided if an agent is not appointed.
7. When an application is made by virtue of section 20(3), 26(6) or 47(4), the appropriate section should be identified at paragraph VII and the number of the earlier application or any patent granted thereon identified.
8. Where the applicant wishes an earlier disclosure of the invention by him at an International Exhibition to be disregarded in accordance with section 14(4)(c), then the "YES" Box at paragraph VIII should be marked. Otherwise the "NO" Box should be marked.
9. Where in disclosing the invention the application refers to one or more micro-organisms deposited with a depositary authority under the Budapest Treaty, then the "YES" Box at paragraph IX should be marked. Otherwise the "NO" Box should be marked.
10. Attention is drawn to rules 90 and 105 of the Patent Rules. Where there are more than three applicants, see also Note 2 above.
11. Applicants resident in Singapore are reminded that if the Registry of Patents considers that an application contains information the publication of which might be prejudicial to the defence of Singapore or the safety of the public, it may prohibit or restrict its publication or communication. Any person resident in Singapore and wishing to apply for patent protection in other countries must first obtain permission from the Singapore Registry of Patents unless they have already applied for a patent for the same invention in Singapore. In the latter case, no application should be made overseas until at least two months after the application has been filed in Singapore.

For Official Use

Application Filing Date : / /
Request received on : / /
Fee received on : / /
Amount :

*Cash/Cheque/Money Order No:

**Delete whichever is inapplicable*

TITLE OF THE INVENTION
GLOBAL REGULATORS OF BACTERIAL PATHOGENIC GENES
AS TARGETS FOR ENGINEERING DISEASE RESISTANCE

CROSS-REFERENCES TO RELATED APPLICATIONS
Not applicable.

5 STATEMENT REGARDING FEDERALLY SPONSORED
RESEARCH OR DEVELOPMENT
Not applicable.

BACKGROUND OF THE INVENTION

1. Field of the Invention
10 The present invention relates to global regulators
of bacterial pathogenic genes, and their use to confer
disease resistance.

2. Description of the Related Art
15 A bibliography follows at the end of the Detailed
Description of the Invention. The listed references
are all incorporated herein by reference.

20 Cell-to-cell communication via small signal
molecules is not only of vital importance to
multi-celled living organisms such as animals and
plants, it also plays important roles in the functional
co-ordination among family members of single-celled
organisms like bacteria. Rapid progress over the last
few years has clearly established that
N-acyl-homoserine lactones, known as autoinducers

9903146-0

(AIs), are widely conserved signal molecules in Gram-negative bacteria. AIs were first found in marine bacteria *Vibrio* species in regulation of bioluminescence (Eberhard, et al., 1981; Cao and Meighen, 1989). In recent years, AIs have been identified in a wide range of Gram-negative bacteria. It has been found that AIs are involved in the regulation of a range of biological functions, including Ti plasmid conjugal transfer in *Agrobacterium tumefaciens* (Zhang, et al., 1993), induction of virulence genes in *Erwinia carotovora*, *Pseudomonas aeruginosa*, *Erwinia stewartii*, *Xenorhabdus nematophilus*, *Erwinia chrysanthemi*, *Pseudomonas solanaceum*, and *Xanthomonas campestris* (Jones, et al., 1993; Passador, et al., 1993; Pirhonen, et al., 1993; Pearson, et al., 1994; Beck von Bodman and Farrand, 1995; Barber, et al., 1997; Clough, et al., 1997; Costa and Loper, 1997; Dunphy, et al., 1997; Nasser, et al., 1998), regulation of antibiotics production in *Pseudomonas aureofaciens* and *Erwinia carotovora* (Pierson, et al., 1994; Costa and Loper, 1997), regulation of swarming motility in *Serratia liquifaciens* (Eberl, et al., 1996), and biofilm formation in *Pseudomonas fluorescens* and *P. aeruginosa* (Allison, et al., 1998; Davies, et al., 1998). Many more bacterial species are known to produce AIs but the biological functions related have not been established yet (Bassler, et al., 1997; Dumenyo, et al., 1998; Cha, et al., 1998).

Different bacterial species could produce different AIs. All AI derivatives share identical homoserine lactone moieties but can differ in the length and the structure of their acyl groups. The key

components in AI-mediated gene regulation systems are LuxI and LuxR type proteins. It has been established now that LuxI-type protein serves as an autoinducer synthase that utilizes acyl-ACPs and AdoMet (S-adenosylmethionine) as substrates (More, et al., 1996; Schaefer, et al., 1996). LuxR-type protein is proposed to be both a receptor for AIs and a AI-dependent transcriptional regulator that binds DNA immediately upstream of the *lux* promoter (Meighen, 1994; Sitnikov, et al., 1995). A 20-nucleotide inverted repeat has been identified which is centered 44 nucleotides upstream of the transcription start site of the luminescence operon. This sequence called *lux* box is required for transcriptional activation by LuxR and is probably the LuxR binding site (Fuqua, et al., 1994). Similar 18-bp *tra* boxes are found upstream of at least three TraR-regulated promoters, and disruption of these elements abolishes transcriptional activation by TraR (Fuqua and Winans, 1996a).

LuxR-type proteins appear to be composed of two modules (Choi and Greenberg, 1991; Hanzelka and Greenberg, 1995). Their carboxyl terminal regions contain a conserved short sequence of 19-amino acid, putative probe-type helix-turn-helix motif, predicted to be involved in binding to target promoters. A general mechanism of activation has been proposed by which the N-terminal domain of LuxR-type protein acts negatively to prevent an interaction between its C-terminal domain and the target DNA binding sites. This inhibition can be relieved by the action of an autoinducer ligand. A strong piece of evidence is that deletion of the N-terminal domain of LuxR results in constitutively active alleles of *luxR*, whereas larger

deletions that remove part of the predicted DNA binding domain abolish transcriptional activation (Choi and Greenberg, 1991). However, other members might use different mechanisms. Recent genetic studies indicate
5 that EsaR and ExpR are likely to be repressors of their target genes rather than activators. Expression of the genes that are repressed by EsaR and ExpR is increased by autoinducers (Beckvon Bodman and Farrand 1995;

10 Throup, et al. 1995). It appears that binding of these proteins to their target sites in promoter region causes repression, therefore autoinducer ligands may act to reduce binding affinity.

Evidence that the autoinducer binding site resides in the amino terminal domain of the LuxR protein has

15 been presented (Hanzelka and Greenberg, 1995). LuxR alleles that have mutated amino terminal region require higher level of this signal that does the wild type, indicating this region required for ligand interaction (Slock, et al., 1990; Shadel, et al., 1990). This
20 region (aa 79-127) and a region within the DNA-binding domain (aa 180-230) show a higher degree of conservation among LuxR and its homologs (ca 50% identity) than other parts of these polypeptides. However, the proposed protein-ligand interaction
25 between LuxR and autoinducer has not been proved yet. Analysis of merodiploid *E. coli* strains containing wild-type and mutant LuxR alleles suggested that LuxR functions as a homomultimer and that a region required for multimerization resides within amino acid residues
30 116 and 161 (Choi and Greenberg, 1992).

BRIEF SUMMARY OF THE INVENTION

In one aspect, the present invention relates to an isolated nucleic acid molecule encoding a bacterial autoinducer inactivation protein.

5 In another aspect, the present invention relates to a expression vector which comprises a nucleic acid molecule encoding a bacterial autoinducer inactivation protein, wherein the expression vector propagates in a procaryotic or eucaryotic cell.

10 In yet another aspect, the present invention relates to a cell of a procaryote or eucaryote transformed or transfected with the expression vector of the present invention.

In yet another aspect, the present invention
15 relates to an isolated protein which has bacterial autoinduction inactivation activity, where the protein comprises the amino acid sequence of SEQ ID NO: 2.

In yet another aspect, the present invention relates to a method for increasing disease resistance
20 in a plant or animal, which method comprises introducing into a cell of such plant or animal a nucleic acid sequence which encodes a bacterial autoinducer inactivation protein in a manner which allows said cell to express said nucleic acid sequence.

25 In yet another aspect, the present invention relates to a method of preventing or reducing bacterial damage to a plant or animal, which method comprises administering to a plant or animal in need of such prevention or reduction an effective amount of a
30 bacterial autoinducer inactivation protein.

In yet another aspect, the present invention relates to a composition for reducing bacterial damage to a plant or animal, which comprises:

- a) an effective amount of a bacterial autoinducer inactivation protein; and
- b) a suitable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 shows the time course of AIs inactivation by cell extracts from *Bacillus* sp. strain 240BI. Cell extracts in 0.2 M phosphate buffer (pH 7.0) containing 100 ug total protein were added to the same buffer containing OHHL in a final concentration of 20 uM. The
10 reaction was conducted in a 1.5 ml Eppendorf centrifuge tube in a final volume of 200 microliters and incubated at 28°C. Same concentration of OHHL in the phosphate
15 buffer was used as control. Samples were taken at 10-min interval till 60 min and the reaction was stopped by boiling for 3 min. The samples were
20 centrifuged for 5 min in a bench top centrifuge at the top speed and then assayed for AIs activity as described (Zhang, 1993). Blue colony indicates the presence of AI that activates the lacZ reporter gene, and white colony indicates absence of AI. Rows from
left to right: 1, OHHL control without protein extract; 2 - 7, samples after 10, 20, 30, 40, 50, 60 min enzyme reaction.

25 Figure 2 shows the estimation of molecular mass of AIs inactivation enzyme. A 600 µl aliquot of cell extracts was added to the Centricon 30 (Amicon) and was centrifuged at a speed of 5000 x g for 30 min at 4°C. Passing fraction (550 microliters) and un-passing fraction (50 microliters) were topped up separately to
30 a final volume of 600 microliters by adding 0.2 M phosphate buffer (pH 7.0). For bioassay, different

amounts of protein samples were added to the tubes containing OHHL in a final concentration of 20 μ M. From row 1 to 6, protein samples added were 2, 4, 6, 8, 10 and 0 μ l and the final reaction volume was 20 microliters for each reaction. Plate A: Passing fraction, Plate B: un-passing fraction.

Figure 3 shows the cloning and deletion analysis of *Bacillus* SP. strain 240B1 AI inactivation region. Cosmid clone E7-R3 contains the 4.3-kb *Eco*RI fragment identified by restriction analysis of overlapping cosmid clones. For deletion analysis, the same fragment was cloned into cloning vector pGEM-7Zf(+) for generation of clone E7-7. The deletion subclones were produced by restriction enzyme digestion and Dnase I treatment from the clone E7-7. The location and direction of *P*tac promoters in the cosmid and in the pGEM-7Zf(+) clone are indicated by arrows. AI inactivation activity of the clones is shown in the second column: +, with AI inactivation activity; -, without AI inactivation activity. Restriction enzymes: E, *Eco*RI; H, *Hind*III; Ev, *Eco*RV; St, *Sty*I. The location and direction of transcription of the *aiiA* ORF is indicated by an open arrow.

Figure 4A shows the nucleotide sequence of the *aiiA* gene [SEQ ID NO:1]. The potential ribosome binding sequence and -10 promoter element are underlined and double underlined respectively. The coding portion starts at base 1. The putative factor-independent termination site is labeled by a thick underline. Figure 4B shows the predicted amino acid sequence of the *aiiA* gene product [SEQ ID NO:2].

A short peptide sequence similar to the aspartyl protease active site consensus motif is underlined.

5 Figure 5 shows the best match of amino acids sequence of *aiiA* gene product (AiiA) to the consensus aspartyl proteases active site motif (Asp). Symbol: X, any amino acid. A vertical line indicates perfect match.

10 Figure 6 shows the bioassay for Als inactivation activities in *Bacillus* sp. strain 240B1, *E. coli* clones and AIs production activity in *Erwinia carotovora* strains. Row 1, OHHL control; row 2, *Bacillus* sp. strain 240B1; row 3, *E. coli* DH5 α ; row 4, *E. coli* DH5 α (pE7-R3); row 5, *E. coli* DH5 α (pF41); row 6, *Erw.* *carotovora* SCG1 (pE7R3); row 7, *Erw. carotovora* SCG1 (pLAFR3); row 8, *Erw. carotovora* SCG1. In the
15 bioassay, OHHL was added to a final concentration of 20 μ M to the samples from lines 1 to 5. No exogenous AIs were added to the samples from rows 6 to 8.

20 Figure 7 shows the effect of *aiiA* gene expression in *Erw. carotovora* on pathogenicity in (A), potato; (B), eggplant; (C), Chinese cabbage; (D), carrot; and (E), celery. Top: plant tissues were inoculated with *Erw. carotovora* SCG1. Bottom: plant tissues were inoculated with *Erw. carotovora* SCG1 (pE7-R3). The
25 actively growing bacteria were centrifuged for 1 min at 3000 x g, resuspended with YEB liquid medium to OD600 = 1.3 (2×10^9 cfu/ml) which was designed as 10^0 inoculum. The 10^0 inoculum was diluted 5 and 10 times respectively to prepare $10^{-1/2}$ and 10^{-1} dilutions. The Plant tissues
30 were inoculated by adding a 4- μ l volume of bacteria

inoculum to the freshly cut surface or a wounding site punched by a pipette tip. The inoculum concentration from the left to the right plate: 10^0 ; $10^{-1/2}$; and 10^{-1} . The inoculated plant tissues were placed in plastic
5 plates and incubated at 28°C. The photograph was taken 48 h after inoculation.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the discovery that the SEQ ID NO:2 protein has the effect of reducing
10 or eliminating the activity of bacterial autoinducers (AIs). Consequently, the protein, and any nucleic acid that encodes the protein, may be used in a variety of situations where it is desired to reduce or eliminate the effect of such bacteria.

15 In one preferred aspect, the present invention provides a nucleic acid molecule which is selected from the group consisting of:

- a) a nucleic acid having the sequence of SEQ ID NO:1;
- 20 b) a nucleic acid encoding the amino acid sequence of SEQ ID NO:2; and
- c) a nucleic acid that hybridizes to a) or b) above, wherein a positive hybridization signal is observed after washing with 1 X SSC and 0.1% SDS at
25 55°C for one hour. The nucleic acid optionally further comprises a signal peptide coding region of any sequence.

The nucleic acid sequence may be used to confer bacterial resistance in plants or animals. A nucleic
30 acid that encodes a bacterial autoinducer inactivation protein can be introduced into a cell such that the

inactivation protein is expressed by the plant or animal.

5 The nucleic acid sequence may be used to confer resistance to diseases where the expression of pathogenic genes are regulated by autoinducers, such as the diseases caused by *Pseudomonas aeruginosa*, *Erwinia stewartii*, *Xenorhabdus nematophilus*, *Erwinia chrysanthemi*, *Pseudomonas solanaceum*, and *Xanthomonas campestris* (Passador, et al., 1993; Pirhonen, et al., 10 1993; Pearson, et al., 1994; Beck von Bodman and Farrand, 1995; Barber, et al., 1997; Clough, et al., 1997; Costa and Loper, 1997; Dunphy, et al., 1997; Nasser, et al., 1998). Preferably, in the agricultural setting, the sequence may be used to confer soft rot 15 disease resistance in susceptible plants, such as potato, eggplant, Chinese cabbage, carrot and celery.

The sequence may be introduced into plant or animal cells by well-known methods. Methods for the transformation or transfection of eukaryotic cells with 20 exogenous nucleic acid sequences include transfection, projectile bombardment, electroporation or infection by *Agrobacterium tumefaciens*. These methods are likewise familiar to the person skilled in the area of molecular biology and biotechnology and need not be explained 25 here in detail. As pathogenic bacteria cells are confined to the intercellular area of plant tissues, it is desirable to target the AiiA protein into the intercellular spaces. Such may be accomplished by fusing a secretion signal peptide to the AiiA protein 30 (Sato, et al., 1995; Firek, et al., 1993; Conrad and Fiedler, 1998; Borisjuk, et al., 1999). Alternatively, a plant membrane attachment motif can be incorporated into the peptide sequence of AiiA for anchoring the

AiiA enzyme in the outer surface of plant cell membrane.

The present invention provides a new strategy for engineering resistance to diseases. In particular, this strategy targets N-acyl homoserine lactone autoinducers that induce expression of pathogenic genes of many bacterial pathogens at a threshold concentration. This strategy is applicable to all plant, animal or mammal diseases where the expression of pathogenic genes of the bacterial pathogens is inducible by N-acyl homoserine lactone autoinducers.

The present invention also contemplates usage of a bacterial autoinducer inactivation protein directly to treat or prevent bacterial damage. For example, the protein may be applied directly to plants in need of such treatment or prevention. In a preferred embodiment, the protein is applied in the form of a composition which comprises an effective amount of the protein and a suitable carrier. The composition may have a wide variety of forms, including solutions, powders, emulsions, dispersions, pastes, aerosols, etc.

The bacterial autoinducer inactivation protein may also be used to treat bacterial infections in animals, including humans. In that application, an effective amount of the active ingredient is administered to an animal in need of such treatment.

For therapeutic treatment, the active ingredient may be formulated into a pharmaceutical composition, which may include, in addition to an effective amount of the active ingredient, pharmaceutically acceptable carriers, diluents, buffers, preservatives, surface active agents, and the like. Compositions may also include one or more other active ingredients if necessary or desirable.

The pharmaceutical compositions of the present invention may be administered in a number of ways as will be apparent to one of ordinary skill in the art. Administration may be done topically, orally, by
5 inhalation, or parenterally, for example.

Topical formulations may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Oral formulations include

10 powders, granules, suspensions or solution in water or non-aqueous media, capsules or tablets, for example. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be used as needed.

Parenteral formulations may include sterile aqueous solutions which may also contain buffers,
15 diluents and other suitable additives.

The dose regimen will depend on a number of factors which may readily be determined, such as severity and responsiveness of the condition to be treated.

20 Aspects of the invention will now be illustrated with reference to the following non-limiting examples.

EXAMPLE 1

Bacterial isolate 240B1 was isolated from soil suspension based on its function for inactivation of
25 N- β -oxo-hexanoyl-L-homoserine lactone (OHHL) and N- β -oxooctanoyl-L-homoserine lactone (OOHL) and N- β -oxodecanoyl-L-homoserine lactone (ODHL) (Zhang, et al., 1993). Unless otherwise stated, OHHL was used for routine bioassay. *Erwinia carotovora* strain SCG1 was
30 isolated from Chinese cabbage leaf showing soft rot symptoms. It has been confirmed that strain SCG1 produces AIs and elicits soft rot disease in potato and

Chinese cabbage. *Escherichia coli* strain DH5 α was used as a host for DNA cloning and subcloning.

Agrobacterium tumefaciens strain NT1 (*traR*;

tra::lacZ749) was used as an indicator in bioassay for

5 AI activity (Piper, et al., 1993). *E. coli* strain was cultured in Luria-Bertani (LB) medium at 37°C and other strains were cultured in LB (Miller, 1972) or YEB medium (per liter contains: casein hydrolysate 10 g,

10 yeast extract 5 g, NaCl 10 g, sucrose 5 g, MgSO₄·7H₂O 0.5 g, agar 15 g, pH 7.2) at 28 °C. The minimal salts medium with mannitol and (NH₄)₂SO₄ as carbon and nitrogen sources was used for bioassay of OHHL (Petit and Tempe, 1978). Appropriate antibiotics were added as indicated at the following concentrations:

15 ampicillin, 100 μ g/ml; tetracycline, 20 μ g/ml and kanamycin, 50 μ g/ml.

Bioassay of AIs activity

The qualitative and quantitative bioassay methods for determination of AIs activity has been described previously (Zhang, 1993). For determination of the AIs production ability of wild-type and genetically modified *Erwinia* strains, the same bioassay procedure was used except that no OHHL was added into the bacterial culture.

25 **Cloning and sequencing of the AiiA gene**

Genomic DNA from 240B1 was digested partially with EcoRI. DNA fragments were ligated to the dephosphorylated EcoRI site of cosmid vector pLAFR3 (Staskawicz, et al., 1987). Ligated DNA was packaged with Gigapack III XL Packaging Extract (Stratagene) and 30 transfected into *E. coli* DH5 α . Cosmid clones with OHHL

inactivation activity were identified by using the bioassay method described above. Subcloning into sequencing vector pGEM-7Zf(+) was carried out by routine techniques (Sambrook, et al., 1989). Deletion analysis was carried out by using DnaseI method as described by Lin, et al. (1985). The sequencing was performed on both strands using the ABI PRISM™ dRhodamine Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems). Nucleic acid sequence data and deduced amino acid sequences were analyzed with a DNASTAR™ sequence analysis software package (DNASTAR Inc.) and database searches were performed using the BLASTA search algorithm (Altschul, et al., 1990).

15 ***Genetic modification of Erwinia strain SCG1***

The E7-R3 plasmid, carrying the *aiiA* gene in the cosmid vector pLAFR3, was transferred into *Erwinia* strain SCG1 by triparental mating with the helper strain RK2013 (Ditta, et al., 1980). Transconjugants were selected on the plates containing minimal medium with tetracycline and confirmed by PCR with primers specific to the *aiiA* gene.

Virulence tests

The virulence of wild-type *Erw. carolovora* strain SCG 1 and the *aiiA* gene transformant SCG1(E7-R3) was evaluated by inoculation. Four µl of early stationary phase bacterial suspension (containing $\sim 2 \times 10^9$ cell/ml) or diluted bacteria was added to the cut surfaces or wounding sites of plant tissues. The inoculated plant tissues were incubated in a Petri dish at 28°C

overnight. The severity of soft rot was examined 48 hours after incubation.

Results

Screening of bacteria that inactivate AIs

5 Bacterial isolates from plant and soil samples were screened for enzymatic inactivation of AIs. A bacterial isolate 240B1, which showed a strong ability
10 to eliminate AIs activity, was selected for further study. The total protein extracts from isolate 240B1 eliminated AIs activity completely during one-hour incubation (Fig. 1), and the capacity of the protein extract to inactivate AIs was abolished by treatment with proteinase K for 1 hour or boiling for 5 min.

15 These observations indicate enzymatic inactivation of AIs by bacterial isolate 240B1. The isolate was taxonomically characterized as *Bacillus* sp., because of the following characteristics: Gram-positive, rod-shaped, catalase positive, facultatively anaerobic, and 16 rRNA sequence homology to that of other *Bacillus*
20 bacteria (data not shown).

 The molecular mass of the enzyme for AIs inactivation appears to be larger than 30 kDa. Its activity was lost after passing the protein extract through Centricon 30 (Amicon) but the activity was
25 recovered in the re-suspended fraction that failed to pass the Centricon 30 (Fig. 2).

Cloning and localization of AIs inactivation region

 To identify the gene encoding AIs inactivation, a cosmid library was constructed with the genomic DNA of
30 *Listeria* sp. strain 240B1. Twelve hundred clones were screened for AIs inactivation activity. Three clones

showing AIs inactivating function were identified. Restriction analysis showed that the 3 clones shared one common band of 4.3-kb generated by *EcoRI* digestion. The bioassay with the subclone E7-7 containing this
5 4.3-kb *EcoRI* fragment confirmed that this fragment encodes AIs inactivation function (Fig. 3). To identify the minimum size and the location of the AIs inactivation gene (*aiiA*), a serial of deletion clones was generated by deletion from both ends of this 4.3-kb
10 fragment with the DNaseI method (Lin, et al., 1985). The results indicated that the *aiiA* gene is contained in a 1.2 Kb fragment in clone F41 (Fig. 3).

AiiA gene encodes a novel protein

The 1.2-kb DNA insert in clone F41 was completely
15 sequenced from both strands. The nucleotide sequence of *aiiA* and the predicted amino acid sequence are shown in Fig. 4. The complete sequence of the DNA insert contains 1,222 base pairs and there are 4 potential in-frame open reading frames (ORF) starting from
20 nucleotide position of 1, 42, 156 and 228 respectively (Fig. 4). Deletion analysis indicated that only the longest ORF encodes AIs inactivation function, because the clone R34, in which the 48 bp promoter region and nucleotides from 1 to 13 in the longest ORF were
25 deleted, lost AI inactivation function completely, although the remaining DNA insert was placed under the control of a functional *Ptac* promoter (Fig. 3). This is confirmed by fusing the longest ORF to the glutathione S-transferase gene in the same ORF and
30 testing for AI inactivation activity of the purified fusion protein (data not shown). This ORF contains 750 bp nucleotide and encodes a protein of 250 amino acids,

with a predicted molecular mass of 28,036 daltons and an isoelectric point at 4.7, because of 19 strongly basic and 39 strongly acidic amino acids residues. The putative initiation codon is preceded at a spacing of 7
5 bp by a potential ribosome-binding sequence (AAGGTGG) which is complementary to the 3' end of the *E. coli* 16S rRNA. The best sequence match (TATTGT) to the consensus -10 promoter element (TATAAT) occurs 35 bp upstream of the initiation codon. A TCTT box following
10 a T-rich region resembling the potential factor-independent termination site is found downstream of the termination codon (Brendel, 1986). The total GC content of the *aiiA* gene is 37% and GC content in the third position of the codon is 27.2%.

15 Database searches showed that the *aiiA* gene has no significant similarity to known sequences in the major databases (GenBank, European Molecular Biology Laboratory, Protein Information Resource, and
20 Swiss-Prot) by FASTA and BLAST analysis at either nucleotide or peptide sequence level, suggesting that *AiiA* is a novel protein. Consensus protein motif search using the Genetics Computer Group (Madison, WI) MOTIF program showed that a short peptide sequence,
25 "ILVDTGMPESAV" from position 47 to 58 in *AiiA*, is similar but not identical to the aspartyl protease active site signature pattern (Rawlings and Barrett, 1995) (Fig. 5).

Expression of aiiA gene in Erwinia carotovora decreases AIs releasing and attenuates virulence

30 The cosmid clone E7-R3 was transferred into *Erwinia carotovora* strain SCG1 by triparental mating. The pLAFR3 vector has been safely maintained in *Erwinia*

carotovora without selection pressure. The bioassay showed that the AIs released by *Erwinia carotovora* (E7-R3) was significantly reduced (Fig. 6, lane 6), while the presence of the cosmid vector pLAFR3 alone in *Erwinia carotovora* did not affect AIs production (Fig. 6, lanes 7). Data suggest that the most of AIs produced by *Erwinia carotovora* strain SCG1 was inactivated by *aiiA* gene product.

The *Erwinia carotovora* SCG1(E7-R3) that expresses AiiA protein failed to or caused only minor soft rot disease symptom in potato, eggplant, Chinese cabbage, carrot and celery, while its parental strain caused severe symptoms (Fig. 7A, B, C, D, E). To prevent experimental errors due to genetic variations, four colonies from *Erwinia carotovora* strain SCG1 and its *aiiA* gene transformants respectively, were randomly selected for testing AIs production and virulence on potato. Similar results were obtained in both experiments. The *Erwinia carotovora* strain SCG1 (pLAFR3) that contains the cosmid vector only caused the same level of disease severity as its parental strain *Erwinia carotovora* strain SCG1 (Fig. 7F).

Discussion

Bacterial isolate 240B I, which was identified as *Bacillus* sp., produces an enzyme that can effectively inactivate the three AIs tested, i.e., N- β -oxo-hexanoyl-L-homoserine lactone, N- β -oxo-octanoyl-L-homoserine lactone and N- β -oxo-decanoyl-L-homoserine lactone. The gene (*aiiA*) encoding the AI inactivation enzyme has been cloned and fully sequenced. Expression of the *aiiA* gene in transformed *E. coli* and pathogenic bacteria *Erwinia carotovora* confers ability for AI

inactivation and significantly reduces the AIs release from *Erwinia carotovora*. To our knowledge, it is the first protein identified capable of enzymatic inactivation of N-acyl-homoserine lactones, the autoinducers for global gene regulation in a diverse of bacteria species.

The AiiA is a novel protein. There is no significant homology to known proteins in major databases. It shares similarities to the consensus pattern of the aspartyl proteases active site (Rawlings and Barret, 1995). Aspartyl proteases, also known as acid proteases, are widely distributed in vertebrates, fungi, plants, retroviruses and some plant viruses. The aspartyl proteases from most retroviruses and some plant viruses are homodimers. The molecular mass of AiiA protein is about 28 kDa but it failed to pass a molecular sieve with a cut off size of 30 kDa, indicating a possibility that AiiA protein exists as a homodimer or homomultimer under the natural conditions. However, there is also a possibility that AiiA monomer has an irregular three-dimensional structure, which hinders it passing through the molecular sieve. Aspartyl proteases are endopeptidases and hydrolyses amide linkages of proteins. Crystallographic study has shown that the enzyme of the aspartyl protease family are bilobed molecules with the active-site cleft located between the lobes, and each lobe contributing one of the pair of aspartic acid residues that is responsible for the catalytic activity (Sielecki et al., 1991).

Erwinia carotovora is a plant pathogen that produces and secretes exoenzymes that act as virulence determinants for soft rot diseases of various plants

including potato, cabbages, tomato, chili, carrot, celery, onion, and lettuce (Kotoujansky, 1987).

5 Mutants that were defective in the producing N-3-(oxohexanoyl)-L-homoserine lactone were also defective in synthesis of the pectinase, cellulase and protease exoenzymes. These mutants failed to induce soft rot disease in potato tubers (Jones, et al., 1993). It was found that the *expI* gene, which is homologous to *luxI* gene of *Vibrio fischeri*, encodes
10 autoinducer production in *Erwinia carotovora*. The *expI* mutant was avirulent when it was inoculated to tobacco leaf but the virulence was restored by external autoinducer addition (Pirhonen, et al., 1993). Obviously, autoinducers are a potential target for

15 genetic engineering of plant soft rot disease resistance. As an interim test and a concept proving approach, the cosmid clone containing the *aiiA* gene was introduced to *Erwinia carotovora* strain SCG1. Expression of the AiiA enzyme in *Erwinia carotovora*
20 significantly reduced the release of autoinducers, and the genetically modified *Erwinia carotovora* that expressed AiiA failed to induce any or induce only minor soft rot disease symptom on all plants tested, including potato, eggplant, Chinese cabbage, carrot and
25 celery. Our results further support the important role of autoinducers in the regulation of expression of virulence genes in *Erwinia carotovora*, and the potential of the *aiiA* gene to confer resistance to soft rot disease and other diseases in which the
30 autoinducers are involved in regulation of pathogenic gene expression.

The present invention provides a new strategy for engineering resistance to diseases. In particular,

this strategy targets N-acyl homoserine lactone autoinducers that induce expression of pathogenic genes of many bacterial pathogens at a threshold concentration. By using the above-mentioned
5 conception-proving approach, the present invention demonstrates that reduction or elimination of autoinducers produced by pathogenic bacteria by an autoinducer inactivation enzyme significantly
attenuates pathogenicity of otherwise virulent
10 bacterial pathogen. Because the expression of pathogenic genes in pathogenic bacteria requires a threshold concentration, this AI-inactivation strategy is applicable to all plant, animal or mammal diseases where the expression of pathogenic genes of the
15 bacterial pathogens is inducible by N-acyl homoserine lactone autoinducers.

The *aiiA* gene could also be a useful tool for investigation of the role of AIs in those bacteria where the biological functions regulated by AIs has not
20 been established. In recent years, many more bacteria species have been shown to produce AIs (Bassler, et al., 1997; Dumenyo, et al., 1998; Cha, et al., 1998; Surette, et al., 1999). Some of them are important plant pathogens such as *Pseudomonas* and *Xanthomonas*
25 species. The gene knock out approach based on sequence homology could be difficult. The overall levels of sequence similarity of AIs synthase and the related regulatory protein from different genera are rather low, often no higher than 28-35% identity between LuxI-
30 type proteins and 18-25% identity for LuxR-type proteins (Fuqua et al., 1996). However, it is feasible and simple to introduce the *aiiA* gene into these

bacteria to probe the biological functions regulated by
AIs.

References

- Allison, D. G. R., B. Sanjose, C. Jaspe, A. Gilbert, P. (1998). Extracellular products as mediators of the formation and detachment of *Pseudomonas fluorescens* biofilms. FEMS Microbiology Letters 167, 179- 184.
- 5
-
- Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990). Basic local alignment search tool. *Journal Molecular Biology* 215, 403-410.
- Barber, C. E., Tang, J. L., Feng, J. X., Pan, M. Q., Wilson, T. J., Slater, H., Dow, J. M., Williams, P., and Daniels, M. J. (1997). A novel regulatory system required for pathogenicity of *Xanthomonas campestris* is mediated by a small diffusible signal molecule. *Molecular Microbiology* 24, 555-566.
- 10
-
- 15 Bassler, B. L., Greenberg, E. P. & Stevens, A. M. (1997). Cross-species induction of luminescence in the quorum-sensing bacterium *Vibrio harveyi*. *Journal of Bacteriology* 179, 4043-4045.
- Beck von Bodman, S., and Farrand, S. K. (1995). Capsular polysaccharide biosynthesis and pathogenicity in *Erwinia stewartii* require induction by an Nacylhomoserine lactone autoinducer. *Journal of Bacteriology* 177, 5000-5008.
- 20
- Borisjuk, N. V., Borisjuk, L. G., Logendra, S., Logendra, S., Petersen, F., Gleba, Y., Raskin, I. 1999. Production of recombinant proteins in plant root exudates. *Nature Biotechnology* 17, 466-469.
- 25

Brendel, V., and Trifonov, E. N. (1984). A computer algorithm for testing potential prokaryotic terminators. *NucleicAcids Research* 12, 4411-4427.

5 Cao, J. G., and Meighen, E. A. (1989). Purification and structural identification of an autoinducer for the luminescence system of *Vibrio harveyi*. *Journal of Biological Chemistry* 264, 21670-21676.

10 Cha, C., Gao, P., Chen, Y. C., Shaw, P. D., and Farrand, S. K. (1998). Production of acyl-homoserine lactone quorum-sensing signals by gram- negative plantassociated bacteria. *Molecular and PlantMicrobe Interactions* 11, 1119-1129.

15 Choi S. H., Greenberg E. P. (1991). The C-terminal region of the *Vibrio fischeri* LuxR protein contains an inducer-independent lux gene activating domain. *Proc. Natl. Acad. Sci. USA* 88, 11115-11119.

20 Choi S. H, Greenberg E. P. (1992). Genetic evidence for multimerization of LuxR, the transcriptional activator of *Vibrio fischeri* luminescence. *Molec. Mar. Biol. Biotech.* 1: 408-413.

25 Clough, S. J., Lee, K. E., Schell, M. A., and Denny, T. P. (1997). A two-component system in *Ralstonia (Pseudomonas) solanacearum* modulates production of PhcAregulated virulence factors in response to 3-hydroxypalmitic acid methyl ester. *J Bacteriol* 179, 3639-3648.

Collmer, A. K., N. T. (1986). The role of pectic enzymes in plant pathogenesis. *Annual Review of Phytopathology* 24, 383-409.

5 Conrad, U., and Fiedler, U. 1998. Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity. *Plant Molecular Biology* 38, 101-109.

10 Costa, J. M. & Loper, J. E. (1997). EcbI and EcbR: homologs of LuxI and LuxR affecting antibiotic and exoenzyme production by *Erwinia carotovora* subsp. *betavascularum*. *Can J Microbiol* 43, 1164-71.

15 Davies, D. G., Parsek, M. R., Pearson, J. P., Iglewski, B. H., Costerton, J. W., and Greenberg, E. P. 1998. The involvement of cell-to-cell signals in the development of a bacterial biofilm. *Science* 280, 295-298.

20 Ditta, G., Stanfield, S., Corbin, D., and Helinski, D. R. (1980). Broad host range DNA cloning system for gram-negative bacteria: construction of a gene bank of *Rhizobium meliloti*. *Proc Natl Acad Sci USA* 77, 7347-7351.

25 Dumenyo, C. K. M., A. Chun, W. Chatterjee, A K. (1998). Genetic and physiological evidence for the production of N-acyl homoserine lactones by *Pseudomonas syringae* pv. *syringae* and other fluorescent plant pathogenic *Pseudomonas* species. *European Journal of Plant Pathology* 104(6). 1998. 569-582. 104, 569-582.

- Dunphy, G., Miyamoto, C., and Meighen, E. (1997). A homoserine lactone autoinducer regulates virulence of an insect-pathogenic bacterium, *Xenorhabdus nematophilus* (Enterobacteriaceae). *J Bacteriol.* 179, 5288-5291.
- 5
- Eberhard, A., Burlingame, A. L., Eberhard, C., Kenyon, G. L., Nealson, K. H., and Oppenheimer, N. J. (1981). Structural identification of autoinducer of *Photobacterium fischeri* luciferase. *Biochemistry* 20, 2444-2449.
- 10
- Eberl, L., Winson, M. K., Sternberg, C., Stewart, G. S. A. B., Christiansen, G., Chhabra, S. R., Bycroft, B., Williams, P., Molin, S. & Givskov, M. (1996). Involvement of N-acyl-L-homoserine lactone autoinducers in controlling the multicellular behaviour of *Serratia liquefaciens*. *Molecular Microbiology* 20, 127- 136.
- 15
- Firek, S., Draper, J., Owen M. R. L., Gandeche, A., Cockburn, B., and Whitelam, G. C. 1993. Secretion of a functional single-chain Fv protein in transgenic tobacco plants and cell suspension cultures. *Plant Molecular Biology* 23, 861-870.
- 20
- Fuqua C, Winans S. C. (1996). Conserved cis-acting promoter elements are required for density-dependent transcription of *Agrobacterium tumefaciens* conjugal transfer genes. *J. Bacteriol.* 178, 435-440.
- 25
- Fuqua W. C., Winans S. C., Greenberg E. P. (1994). Quorum sensing in bacteria: the LuxR/LuxI family of

cell density-responsive transcriptional regulators. *J. Bacteriol.* 176, 269-75.

- 5 Fuqua, C., Winans, S. C., and Greenberg, E. P. (1996). Census and consensus in bacterial ecosystems: The LuxR-LuxI family of quorum-sensing transcriptional regulators. *Annu. Rev. Microbiol.* 50, 727-751.

-
- 10 Hanzelka, B. L., Greenberg, E. P. (1995). Evidence that the N-terminal region of the *Vibrio fischeri* LuxR protein constitutes an autoinducer-binding domain. *J. Bacteriol.* 177, 815-817.

-
- 15 Jones, S. M., Yu, B., Bainton, N. J., Birdsall, M., Bycroft, B. W., Chhabra, S. R., Cox, A. J. R., Golby, P., Reeves, P. J., Stephens, S.; Winson, M. K., Salmond, G. P. C., Stewart, G. S. A. B., and Williams, P. (1993). The *Lux* autoinducer regulates the production of exoenzyme virulence determination in *Erwinia carotovora* and *Pseudomonas aeruginosa*. *EMBO J* 12, 2477-2482.

- 20 Kotoujansky, A. (1987). Molecular genetics of pathogenesis by soft-rot *Erwinias*. *Annual Review of Phytopathology* 25, 405-430.

Lin, H. C., Lei, S. P., and Wilcox, G. (1985). An improved DNA sequencing strategy. *Anal Biochem* 147, 114-119.

- 25 Meighen, E. A. (1994). Genetics of bacterial luminescence. *Annu. Rev. Genet.* 28, 117-139.

More, M. I., Finger, L. D., Stryker, J. L., Fuqua, C., Eberhard, A. & Winans, S. C. (1996). Enzymatic synthesis of a quorum-sensing autoinducer through use of defined substrates. *Science* 272, 1655-1658.

- 5 Nasser, W., Bouillant, M. L., Salmond, G. & Reverchon, S. (1998). Characterization of the *Erwinia chrysanthemi* *expI-expR* locus directing the synthesis of two N-acyl-homoserine lactone signal molecules. *Molecular Microbiology* 29, 1391-1405.
-

- 10 Passador, L., Cook, J. M., Gambello, M. J., Rust, L., Iglewski, B. H. (1993). Expression of *Pseudomonas aeruginosa* virulence genes requires cell-to-cell communication. *Science* 260, 1127- 1130.
-

- 15 Pearson, J. P., Gray, K. M., Passador, L., Tucker, K. D., Eberhard, A., Iglewski, B. H., and Greenberg, E. P. (1994). Structure of the autoinducer required for expression of *Pseudomonas aeruginosa* virulence genes. *Proc Natl Acad Sci USA* 91, 197-201.

- 20 Petit, A., and Tempe, J. (1978). Isolation of *Agrobacterium* Ti plasmid regulatory mutants. *Mol. Gen. Genet.* 167, 147-155.

- 25 Pierson, L. S., 3rd, Keppenne, V. D., and Wood, D. W. (1994). Phenazine antibiotic biosynthesis in *Pseudomonas aureofaciens* 30-84 is regulated by PhzR in response to cell density. *J. Bacteriol.* 176, 3966-74.

Piper, K. R., Beck von Bodman, S., and Farrand, S. K. (1993). Conjugation factor of *Agrobacterium tumefaciens*

regulates Ti plasmid transfer by autoinduction. *Nature* 362, 448-450.

- 5 Pirhonen, M., Flego, D., Heikinheimo, R., and Palva, E. (1993). A small diffusible signal molecule is responsible for the global control of virulence and exoenzyme production in the plant pathogen *Erwinia carotovora*. *EMBO J* 12, 2467-2476.
-

- 10 Rawlings, N. D. B., A. J. (1995). Families of aspartic peptidases, and those of unknown catalytic mechanism. In *Methods in Enzymology*, pp. 105-180. Edited by A. J. Barrett. New York: Academic Press.
-

- Sambrook, J. F., E. F. Maniatis, T. (1989). *Molecular Cloning*, Second edn. New York: Cold Spring Harbor Laboratory Press.
- 15 Sato, F., Koiwa, H., Sakai, Y., Yamada, Y. (1995). Synthesis and secretion of tobacco neutral PR-5 protein by transgenic tobacco and yeast. *Biochemical & Biophysical Research Communications*. 211, 909-913.
- 20 Schaefer, A. L. V., D L. Hanzelka, B L. Cronan, J E Jr. Greenberg, E P. (1996). Generation of cell-to-cell signals in quorum sensing: Acyl homoserine lactone synthase activity of a purified *Vibrio fischeri* LuxI protein. *Proceedings of the National Academy of Sciences of the United States of America* 93, 9505-9509.
- 25 Shadel, G. S., Young, R., Baldwin, T. O. (1990). Use of regulated cell lysis in a lethal genetic selection in *Escherichia coli*: identification of the

autoinducer-binding region of the LuxR protein from
Vibrio fischeri ATCC 7744. *J. Bacteriol.* 172, 3980-3987.

Sielecki, A. R., Fujinaga, M., Read, R. J. & James, M.
N. (1991). Refined structure of porcine pepsinogen at
5 1.8 Å resolution. *J Mol Biol* 219, 671-692.

Sitnikov, D., Schineller, J. B., Baldwin, T. O. (1995).
Transcriptional regulation of bioluminescence genes
from *Vibrio fischeri*. *Mol. Microbiol.* 17, 801-12.

10 Slock J, Kolibachuk D, Greenberg EP. (1990). Critical
regions of the *Vibrio fischeri* LuxR protein defined by
mutational analysis. *J. Bacteriol.* 172: 3974-3979.

15 Staskawicz, B. D., D. Keen, N. T. and Napoli, C.
(1987). Molecular characterization of cloned avirulence
genes from race 0 and race I of *Pseudomonas syringae*
pv. *glycinea*. *Journal of Bacteriology* 169, 5789-5794.

Surette, M. G. B., B L. (1998). Quorum sensing in
Escherichia coli and *Salmonella typhimurium*.
Proceedings of the National Academy of Sciences of the
United States of America. 95, 7046-7050.

20 Throup, J. P., Camara, M., Briggs, G. S., Winson, M.
K., Chhabra, S. R., et al. (1995). Characterisation of
the *yenI/yenR* locus from *Yersenia enterocolitica*
mediating the synthesis of two N-acylhomoserine lactone
signal molecules. *Mol. Microbiol.* 17, 345-356.

25 Zhang, L.-H. (1993). Molecular biology and biochemistry
of a novel conjugation factor in *Agrobacterium*.

Doctoral Dissertation, The Adelaide University,
Australia.

Zhang, L.-H., Murphy, P. J., Kerr, A., and Tate, M. E.
(1993). *Agrobacterium* conjugation and gene regulation
5 by N-acyl-L-homoserine lactones. *Nature* 362, 446-447.

CLAIMS

1. An isolated nucleic acid molecule encoding a bacterial autoinducer inactivation protein.

2. The molecule of claim 1, wherein the nucleic acid molecule is selected from the group consisting of:

a) a nucleic acid having the sequence of the coding portion of SEQ ID NO:1;

b) a nucleic acid encoding the amino acid sequence of SEQ ID NO:2; and

c) a nucleic acid that hybridizes to a) or b) above, wherein a positive hybridization signal is observed after washing with 1 X SSC and 0.1% SDS at 55°C for one hour.

3. The molecule of claim 1, which further comprises a signal peptide coding region of any sequence.

4. An expression vector which comprises the nucleic acid molecule of claim 1, wherein the expression vector propagates in a procaryotic or eucaryotic cell.

5. A cell of a procaryote or eucaryote transformed or transfected with the expression vector of claim 4.

6. An isolated protein which has bacterial autoinduction inactivation activity, where the protein comprises the amino acid sequence of SEQ ID NO: 2.

7. A method for increasing disease resistance in a plant or animal, which method comprises introducing

into a cell of such plant or animal a nucleic acid sequence which encodes a bacterial autoinducer inactivation protein in a manner which allows said cell to express said nucleic acid sequence.

5 8. The method of claim 7, wherein the nucleic acid sequence is selected from the group consisting of:

- a) a nucleic acid having the sequence of the coding portion of SEQ ID NO:1;
 - b) a nucleic acid encoding the amino acid sequence of SEQ ID NO:2.
- 10

9. The method of claim 7 or 8, wherein the nucleic acid sequence further comprises a signal peptide coding region of any sequence.

15 10. The method of claim 7 or 8, wherein the nucleic acid sequence further comprises a membrane attachment domain-coding region of any source.

11. The method of claim 7, wherein the plant is susceptible to bacterial soft rot disease.

20 12. The method of claim 11, wherein the plant is selected from the group consisting of potato, eggplant, Chinese cabbage, carrot and celery.

25 13. The method of claim 7, wherein the plant is susceptible to a bacterial disease in which the expression of a virulence gene is regulated by an N-acyl homoserine lactone autoinducer.

14. A method of preventing or reducing bacterial damage to a plant or animal, which method comprises

administering to a plant or animal in need of such prevention or reduction an effective amount of a bacterial autoinducer inactivation protein.

5 15. The method of claim 14, wherein the protein comprises SEQ ID NO: 2.

16. A composition for preventing or reducing bacterial damage to a plant or animal, which comprises:

- 10 a) an effective amount of a bacterial autoinducer inactivation protein; and
b) a suitable carrier.

17. The composition of claim 16, wherein the protein comprises SEQ ID NO: 2.

18. A method for screening of bacterial isolates for autoinducer inactivation activity, which comprises:

- 15 a) isolating a single colony bacterial culture from soil or plant samples;
b) screening the culture for autoinducer inactivation activity;
c) preparing a crude protein extract from the
20 culture; and
d) confirming enzymatic inactivation of autoinducer activity by the crude protein extract.

19. A method of isolating the nucleic acid of claim 1 or claim 2, which comprises the steps of:

- 25 a) preparing a gene bank from a donor organism that contains a nucleic acid sequence coding for a protein with an autoinducer inactivation activity in a suitable host organism;
b) screening the clones of the gene bank; and

c) isolating the clones which contain a nucleic acid coding for a protein with autoinducer inactivation activity.

20. A process as claimed in claim 19, wherein *E. coli* is used as host organism.

21. A process as claimed in claim 19, wherein the steps of preparing a gene bank, screening the clones, and isolating the clones are performed in an *E. coli* strain that does not inactivate the autoinducer.

10 22. A method which comprises:

a) introducing the nucleic acid sequence of claim 1 or claim 2 into a bacterial cell; and
b) screening the bacterial cell obtained from step a) for changed biological function.

15 23. The method of claim 22, wherein the changed biological function is a function which is lost as a result of step a).

20 24. The method of claim 22, wherein the changed biological function is a function which is suppressed as a result of step a).

25. The method of claim 22, wherein the changed biological function is a function which is enhanced as a result of step a).

ABSTRACT OF THE DISCLOSURE

Disclosed are an isolated nucleic acid molecule encoding a bacterial autoinducer inactivation protein, the encoded protein, and anti-bacterial uses therefor.

CR	1	2	3	4	5	6
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31	32	33	34	35
36	37	38	39	40	41	42
43	44	45	46	47	48	49
50	51	52	53	54	55	56
57	58	59	60	61	62	63
64	65	66	67	68	69	70
71	72	73	74	75	76	77
78	79	80	81	82	83	84
85	86	87	88	89	90	91
92	93	94	95	96	97	98
99	100	101	102	103	104	105
106	107	108	109	110	111	112
113	114	115	116	117	118	119
120	121	122	123	124	125	126
127	128	129	130	131	132	133
134	135	136	137	138	139	140
141	142	143	144	145	146	147
148	149	150	151	152	153	154
155	156	157	158	159	160	161
162	163	164	165	166	167	168
169	170	171	172	173	174	175
176	177	178	179	180	181	182
183	184	185	186	187	188	189
190	191	192	193	194	195	196
197	198	199	200	201	202	203
204	205	206	207	208	209	210
211	212	213	214	215	216	217
218	219	220	221	222	223	224
225	226	227	228	229	230	231
232	233	234	235	236	237	238
239	240	241	242	243	244	245
246	247	248	249	250	251	252
253	254	255	256	257	258	259
260	261	262	263	264	265	266
267	268	269	270	271	272	273
274	275	276	277	278	279	280
281	282	283	284	285	286	287
288	289	290	291	292	293	294
295	296	297	298	299	300	301
302	303	304	305	306	307	308
309	310	311	312	313	314	315
316	317	318	319	320	321	322
323	324	325	326	327	328	329
330	331	332	333	334	335	336
337	338	339	340	341	342	343
344	345	346	347	348	349	350
351	352	353	354	355	356	357
358	359	360	361	362	363	364
365	366	367	368	369	370	371
372	373	374	375	376	377	378
379	380	381	382	383	384	385
386	387	388	389	390	391	392
393	394	395	396	397	398	399
400	401	402	403	404	405	406
407	408	409	410	411	412	413
414						

Figure 2





Figure 3



gr26

Figure 4(A)

..ctttactgt <u>attt</u> gtttttattcaaaactaaatgtaaaggtggatacata	-1
ATGACAGTAAAGAAGCTTTATTTTCGTCCCAGCAGGTCGTTGTATGTTGGA	50
TCATTCGTCTGTTAATAGTACATTAACACCAGGAGAATTATTAGACTTAC	100
<hr/>	
CGGTTTGGTGTATCTTTTGGAGACTGAAGAAGGACCTATTTTAGTAGAT	150
ACAGGTATGCCAGAAAGTGCAGTTAATAATGAAGGTCTTTTAAACGGTAC	200
ATTTGTCTGAAGGGCAGGTTTACCGAAAATGACTGAAGAAGATAGAATCG	250
TGAATATTTTAAAACGGGTTGGTTATGAGCCGGAAGACCTTCTTTATATT	300
<hr/>	
ATTAGTTCTCACTTGCATTTTGATCATGCAGGAGGAAATGGCGCTTTTAT	350
AAATACACCAATCATTGTACAGCGTGCTGAATATGAGGCGGCGCAGCATA	450
GCGAAGAATATTTGAAAGAATGTATATTGCCGAATTTAAACTACAAAATC	500
ATTGAAGGTGATTATGAAGTCGTACCAGGAGTTCAATTATTGCATACACC	550
AGGCCATACTCCAGGGCATCAATCGCTATTAATTGAGACAGAAAAATCCG	600
GTCCTGTATTATTAACGATTGATGCATCGTATACGAAAGAGAATTTTGAA	650
AATGAAGTGCCATTTGCGGGATTTGATTCAGAATTAGCTTTATCTTCAAT	700
TAAACGTTTAAAAGAAGTGGTGATGAAAGAGAAGCCGATTGTTTTCTTTG	750
GACATGATATAGAGCAGGAAAGGGGATGTAAAGTGTTCCCTGAATATATA	800
TAGtaca ⁹²⁶ aaaagtcatgagcttattcgctcatgacttttttcgtttaa ⁹²⁶ atg	850
Attttttttaaataagttataaactttttttagaactat <u>cttt</u> cattttaattg	900
Atagtacgtaagggtttacatcattaggagtatcttggttgagcaatcatca	950
Cttcgttactgtgatgggtcaactacccatatgaaatattttttataagtc	1000
Ccatcctcgaaagtaatccacatatcacagtctattaaatctgatccttc	1050
Ttcatcta ⁹²⁶ atgttaatttttccttttttggcggtatccatactgttaatga	1100
Atgttttttaattcatctgtttttgtgagaaagatatccttttttgtttta	1150

Attgactcgacatgtatatcttttatttcttgtttctctaaaaagacagg 1200
 gggctcatttgggtctcttttgagt 1222

Figure 4(B)

MTVKKLYFVPAGRCMLDHSSVNSTLTTPGELLDLPVWCYLLTEEGPILVD 50

TGMPESAVNNEGLFNGTFVEGQVLPKMTEEDRIVNILKRVGYEPEDLLYI 100

ISSHLHFDHAGGNGAFINTPIIVQRAEYEAQHSSEYLKECILPNLNYKI 150

IEGDYEVVPGVQLLHTPGHTPGHQSLLIETEKSGPVLLTIDASYTKENFE 200

NEVPFAGFDSELALSSIKRLKEVVMKEKPIVFFGHDIEQERGCKVFPEYI 250

Figure 5

Asp: [LIVMEGAC] - [LIVMTADN] - [LIVESA] - D - [ST] - G - [STAV] -

AiiA:	I ₄₇		L		V	D	T	G M

Asp: [STAPDENQ] - X - [LIVMFSTNC] - X - [LIVMFGTA]

AiiA:	P		E		S	A V ₅₈

gzh

Figure 6




Figure 7

